Claims

1. A combination of (i) a BCL-2 inhibitor and (ii) SEL24/MEN1703 for use as medicament.

2. Use of (i) a BCL-2 inhibitor and (ii) SEL24/MEN1703 in the manufacture of a medicament for combination therapy to treat a patient suffering from cancer.

3. Use of (i) a BCL-2 inhibitor in the manufacture of a first medicament and use of (ii) SEL24/MEN1703 in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat a patient suffering from cancer.

4. Use of (i) a BCL-2 inhibitor in the manufacture of a medicament for use in combinatorial therapy for treating a patient suffering from cancer, wherein said medicament is to be administered in combination with (ii) SEL24/MEN1703.

5. The use according to any one of claims 2 to 4, wherein the cancer is a hematological cancer.

6. The use according to any one of claims 2 to 5, wherein the cancer is acute myeloid leukemia (AML).

7. The use according to any one of claims 2 to 4, wherein the BCL-2 inhibitor is Venetoclax.

8. The use according to claim 7, wherein Venetoclax is to be administered at a daily dose of 50 mg to 600 mg.

9. The use according to any one of claims 2 to 8, wherein SEL24/MEN1703 is to be administered at a daily dose of 50 mg to 150 mg.

10. The use according to any one of claims 2 to 9, wherein the combination further comprises (iii) a hypomethylating agent or cytarabine.

11. The use according to claim 10, wherein the hypomethylating agent is selected from the group consisting of azacitidine, decitabine, CC-486 and ASTX727.

12. The use according to claim 10 or 11, wherein the hypomethylating agent is to be administered at a daily dose of 10 mg/m^2 to 100 mg/m^2.

13. The use according to claim 12, where the hypomethylating agent is azacitidine and the azacitidine is to be administered at a daily dose of about 75 mg/m^2.

14. The use according to claim 12, where the hypomethylating agent is decitabine and the decitabine is to be administered at a daily dose of about 20 mg/m^2.

15. The use according to claim 10, wherein cytarabine is to be administered at a daily dose of about 20 mg/m^2.

16. A kit of dosage forms comprising (i) a dosage form comprising a BCL-2 inhibitor and (ii) a dosage form comprising SEL24/MEN1703.

17. A dosage form comprising (i) a BCL-2 inhibitor and (ii) SEL24/MEN1703.